Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4301806 | 1.00 | HSD11B1 (0.77) | HSD11B1EPHX2 | |
| SCHEMBL1014945 | 0.98 | HSD11B1 (0.74) | HSD11B1 | |
| SCHEMBL1014944 | 0.98 | HSD11B1 (0.74) | HSD11B1 | |
| SCHEMBL1018154 | 0.96 | HSD11B1 (0.76) | HSD11B1 | |
| SCHEMBL1018155 | 0.96 | HSD11B1 (0.76) | HSD11B1 | |
| SCHEMBL1012569 | 0.87 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL1012570 | 0.87 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL1587456 | 0.87 | HSD11B1 (0.67) | HSD11B1EPHX2 | |
| SCHEMBL1587035 | 0.87 | HSD11B1 (0.67) | HSD11B1EPHX2 | |
| SCHEMBL1014979 | 0.85 | HSD11B1 (0.78) | HSD11B1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | claimed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | HSD11B1 2/4885EPHX2 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.